DEFA14A: Dynavax Faces Potential Boardroom Battle as Deep Track Seeks Control

Dynavax files preliminary proxy statement amid a contested director election at the 2025 Annual Meeting, highlighting a disagreement with Deep Track over the company's strategic direction.

Summary

• Dynavax Technologies Corporation has filed its preliminary proxy materials for the 2025 Annual Meeting of Stockholders.
• The filing details a disagreement with Deep Track, an investor seeking control of the board.
• Dynavax's board has nominated four independent directors for reelection: Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun.
• The company emphasizes its strong financial and operational performance, including record 2024 revenues for HEPLISAV-B of $268 million and an estimated 44% total market share in the U.S.
• Dynavax expects net product revenue of $305 million to $325 million in 2025.
• The company has returned capital to stockholders through a $200 million share repurchase program.
• Deep Track's plan is to position Dynavax as a single-asset company with high-cost debt, over-lever the Company and collateralize the Company's foundational commercial asset in order to return capital immediately to stockholders.
• Dynavax believes Deep Track's plan is short-sighted and jeopardizes long-term growth opportunities.
• The board has made multiple settlement proposals to Deep Track, all of which were rejected or met with changing demands.
• Dynavax is open to adding qualified directors but found Deep Track's fund representative unqualified due to a lack of relevant skills and experience.
• The company urges stockholders to read the proxy statement and other relevant documents carefully.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company highlights strong financial performance and growth prospects, the ongoing proxy battle introduces uncertainty and potential risks.

Positives

• Dynavax has achieved record financial and operational results.
• HEPLISAV-B is the market share leader in the U.S. adult Hepatitis B market.
• The company has a disciplined and balanced capital allocation framework.
• Dynavax has a proven track record of growth and value creation, driven by strategic investment and operational excellence that has delivered total stockholder returns of approximately 300% over the past five years.
• The Board has been thoughtful in identifying industry leaders with highly specialized skillsets that are directly relevant to the Company.

Negatives

• Dynavax is facing a proxy battle with Deep Track, indicating a disagreement on the company's strategic direction.
• Deep Track's plan is to position Dynavax as a single-asset company with high-cost debt, over-lever the Company and collateralize the Company's foundational commercial asset in order to return capital immediately to stockholders.
• The Board interviewed Deep Track's fund representative and found him unqualified to serve as a director based on a lack of relevant skills and experience.

Risks

• The proxy contest with Deep Track could distract management and create uncertainty.
• Deep Track's proposed strategy could jeopardize long-term value creation.
• The company's future performance is subject to risks and uncertainties inherent in the biopharmaceutical industry, including commercialization and supply risks.

Future Outlook

Dynavax expects 2025 to be a banner year with expected net product revenue of $305 million to $325 million. The company aims to build sustainable growth and continued category leadership by investing in internal assets leveraging its novel vaccine adjuvant technology, CpG 1018.

Management Comments

• Dynavax's strategy is working, and the Board and management team are best positioned to build on the Company's momentum.
• The Dynavax Board remains unwavering in its commitment to act in the best interests of the Company and all stockholders, not only those of Deep Track.

Industry Context

The proxy battle highlights the increasing activism in the biopharmaceutical industry, where companies with promising products but differing strategic visions become targets for activist investors. The focus on HEPLISAV-B and the potential abandonment of other pipeline programs reflects a common debate between short-term profitability and long-term growth in the sector.

Comparison to Industry Standards

• Dynavax's 300% total stockholder returns over the past five years significantly exceed the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, suggesting strong relative performance.
• HEPLISAV-B's market share leadership in the U.S. adult Hepatitis B market positions it favorably against competitors like GlaxoSmithKline's Engerix-B and Merck's Recombivax HB.
• The company's focus on CpG 1018 adjuvant technology aligns with the industry trend of developing novel vaccine adjuvants to enhance immune responses.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face a choice between the current board's strategy and Deep Track's proposed plan.
• Employees may experience uncertainty due to the potential changes in company strategy and leadership.
• Customers and suppliers could be affected by any shifts in Dynavax's business focus.

Next Steps

• Dynavax will provide stockholders with additional information as the 2025 Annual Meeting approaches.
• The company will file a definitive proxy statement with the SEC.
• Stockholders will vote on the election of directors and the proposed board declassification at the 2025 Annual Meeting.

Key Dates

Keywords

Dynavax, Deep Track, proxy statement, HEPLISAV-B, board of directors, annual meeting, stockholders, vaccines, governance, declassification